CN111436193A - 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血 - Google Patents

通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血 Download PDF

Info

Publication number
CN111436193A
CN111436193A CN201880057599.9A CN201880057599A CN111436193A CN 111436193 A CN111436193 A CN 111436193A CN 201880057599 A CN201880057599 A CN 201880057599A CN 111436193 A CN111436193 A CN 111436193A
Authority
CN
China
Prior art keywords
rvwf
vwf
infusion
bleeding
von willebrand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057599.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·查普曼
B·埃文斯汀
B·普罗德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Baishen Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baishen Co filed Critical Baxalta GmbH
Publication of CN111436193A publication Critical patent/CN111436193A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880057599.9A 2017-07-07 2018-07-09 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血 Pending CN111436193A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530027P 2017-07-07 2017-07-07
US62/530,027 2017-07-07
PCT/US2018/041320 WO2019010497A1 (en) 2017-07-07 2018-07-09 TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION

Publications (1)

Publication Number Publication Date
CN111436193A true CN111436193A (zh) 2020-07-21

Family

ID=63036433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057599.9A Pending CN111436193A (zh) 2017-07-07 2018-07-09 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血

Country Status (15)

Country Link
US (5) US10632176B2 (enExample)
EP (2) EP3648788B1 (enExample)
JP (2) JP7307047B2 (enExample)
KR (1) KR20200037235A (enExample)
CN (1) CN111436193A (enExample)
AU (2) AU2018298233B2 (enExample)
BR (1) BR112020000321A2 (enExample)
CA (1) CA3069295A1 (enExample)
CO (1) CO2020001322A2 (enExample)
DK (1) DK3648788T3 (enExample)
ES (1) ES2986574T3 (enExample)
FI (1) FI3648788T5 (enExample)
PL (1) PL3648788T3 (enExample)
PT (1) PT3648788T (enExample)
WO (1) WO2019010497A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF
CA3128498A1 (en) 2019-02-01 2020-08-06 Bjorn Mellgard Methods of prophylactic treatment using recombinant vwf (rvwf)
US20220395560A1 (en) * 2019-02-01 2022-12-15 Takeda Pharmaceutical Company Limited METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US6005077A (en) 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
KR101423344B1 (ko) 2006-01-04 2014-07-30 백스터 인터내셔널 인코포레이티드 올리고펩티드-무함유 세포 배양 배지를 이용하여 단백질을 발현시키는 방법
DK2167117T3 (da) 2007-06-13 2012-11-19 Csl Behring Gmbh Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser
EP2222329A1 (en) 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
AU2008345135C1 (en) 2007-12-28 2015-04-30 Takeda Pharmaceutical Company Limited Recombinant VWF formulations
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CN103919736A (zh) 2008-10-21 2014-07-16 巴克斯特国际公司 冻干的重组vwf配方
JP2013500743A (ja) 2009-08-04 2013-01-10 バクスター・インターナショナル・インコーポレイテッド Ｆｖｉｉｉおよびｖｗｆがノックアウトされた遺伝子導入マウス−血友病ａモデル
CN103097522A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组adamts13的方法
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
AU2018298233B2 (en) 2017-07-07 2025-04-24 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant VWF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AUGUSTO B. FEDERICI: "Prophylaxis of bleeding episodes in patients with von Willebrand\'s disease" *
JOAN C. GILL等: "Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease" *
M. SINGAL等: "Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease" *
MASSIMO FRANCHINI等: "Gastrointestinal angiodysplasia and bleeding in von Willebrand disease" *
PIER MANNUCCIO MANNUCCI等: "Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial" *

Also Published As

Publication number Publication date
EP4424366A3 (en) 2024-12-04
EP3648788B1 (en) 2024-05-22
CO2020001322A2 (es) 2020-02-18
ES2986574T3 (es) 2024-11-12
PT3648788T (pt) 2024-08-23
US20230122958A1 (en) 2023-04-20
US10632176B2 (en) 2020-04-28
JP2020526525A (ja) 2020-08-31
WO2019010497A1 (en) 2019-01-10
RU2020105682A3 (enExample) 2021-10-15
US20210169989A1 (en) 2021-06-10
US10905746B2 (en) 2021-02-02
PL3648788T3 (pl) 2024-10-07
JP7307047B2 (ja) 2023-07-11
JP7641327B2 (ja) 2025-03-06
KR20200037235A (ko) 2020-04-08
EP3648788A1 (en) 2020-05-13
US20190091299A1 (en) 2019-03-28
US20240316160A1 (en) 2024-09-26
CA3069295A1 (en) 2019-01-10
AU2018298233B2 (en) 2025-04-24
DK3648788T3 (da) 2024-08-19
FI3648788T3 (fi) 2024-08-16
BR112020000321A2 (pt) 2020-07-14
US11529395B2 (en) 2022-12-20
FI3648788T5 (fi) 2024-09-09
AU2018298233A1 (en) 2020-01-30
EP4424366A2 (en) 2024-09-04
JP2023123738A (ja) 2023-09-05
RU2020105682A (ru) 2021-08-10
US20200206318A1 (en) 2020-07-02
US12016904B2 (en) 2024-06-25
AU2025205392A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP2025128168A (ja) 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
US20220395560A1 (en) METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF)
CN111565741A (zh) 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
HK40115617A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf
RU2774720C2 (ru) ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ
EA047451B1 (ru) СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
HK40064201A (en) Methods of prophylactic treatment using recombinant vwf (rvwf)
HK40029176B (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40029176A (en) Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
HK40031159A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210706

Address after: Osaka

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Applicant before: Baishen Co.

Applicant before: BAXALTA GmbH

TA01 Transfer of patent application right